− Oral Data Presentation to be Featured in “Highlights of ASH” −

New Orleans, LA & Osaka, Japan (Press Release) - Takeda Pharma­ceu­tical Company Limited (TSE:4502) today announced final Phase 1 and pre­lim­i­nary Phase 2 results of a study combining oral inves­ti­ga­tional MLN9708 admin­istered twice a week with lena­lido­mide and dexa­meth­a­sone in patients with newly diag­nosed multiple myeloma (MM). The investigators reported a com­bined com­plete response and very good partial response (CR+VGPR) rate of 76 per­cent (46/62) and a 94 per­cent over­all response rate (ORR; 58/62 ≥ partial response). Stringent com­plete response (sCR) was reached in 75 per­cent of patients …

Study is one of more than 160 abstracts eval­u­ating 10 Celgene com­­pounds across a range of blood cancers

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that data from FIRST^® (Frontline Investigation of Lena­lido­mide + Dexa­meth­a­sone Versus Standard Thalido­mide), its phase III study (MM-020/IFM 07-01) of REV­LI­MID® (lena­lido­mide) in com­bi­na­tion with dex­a­meth­a­sone in patients newly diag­nosed with multiple myeloma (NDMM) in­eli­gible for stem cell trans­plant will be presented on Sunday, Dec. 8 during the plenary session of the 55^thAmerican Society of Hematology annual meeting in New Orleans, La.

Abstracts for the meeting were released today on the society’s …

Researchers from the Moffitt Cancer Center recently published results from a Phase 2 clinical trial that investigated the combination of Revlimid plus Doxil and low-dose dexa­metha­sone as initial therapy for patients with newly diag­nosed multiple myeloma.

Although the results show an overall re­sponse rate of 77 per­cent, a medi­an progression-free survival time of 28 months, and a one-year overall survival rate of 98 per­cent for the Revlimid (lenalidomide), Doxil (doxo­ru­bi­cin liposomal), and dexa­metha­sone (Decadron) combination, the re­search­ers indicate that this combination is not an improvement on …

Decision could sig­nif­i­cantly im­prove trans­plant out­comes for patients with multiple myeloma

Beerse, Belgium (Press Release) - Janssen-Cilag Inter­na­tional NV (Janssen) announced today that the European Com­mis­sion (EC) has approved the use of VELCADE^® (bor­tez­o­mib) as induction ther­apy (a first thera­peutic option) in com­bi­na­tion with dexa­meth­a­sone (VD) or thalido­mide and dexa­meth­a­sone (VTD).[1] This licence extension will apply to adult patients with pre­vi­ously-untreated multiple myeloma who are eligi­ble for high-dose chemo­ther­apy with haematological stem cell trans­plan­ta­tion.

Until now, VELCADE’s (bor­tez­o­mib) indi­ca­tion has been limited to its use, in com­bi­na­tion with mel­phalan and pred­ni­sone, in adult patients with multiple myeloma that are pre­vi­ously untreated and in­eli­gible for stem …

Statistically sig­nif­i­cant im­prove­ment in pro­gres­sion-free survival dem­onstrated

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID^® (lena­lido­mide) in com­bi­na­tion with dexa­meth­a­sone in patients newly diag­nosed with multiple myeloma met its pri­mary end­point of pro­gres­sion-free survival (PFS). In the study, a doublet regi­men of continuous oral lena­lido­mide in com­bi­na­tion with low-dose dexa­meth­a­sone (Rd) dem­onstrated a statistically sig­nif­i­cant im­prove­ment in PFS compared to patients receiving a comparator arm with a triplet regi­men consisting of mel­phalan, pred­ni­sone and thalido­mide (MPT).

One of the largest phase III …

Label updates could lead to sig­nif­i­cantly im­proved out­comes for patients with multiple myeloma

Beerse, Belgium (Press Release) - Janssen-Cilag Inter­na­tional NV (Janssen) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) has granted a positive opinion on two variations relating to the use of VELCADE®.[1] VELCADE® is indicated for the treat­ment of multiple myeloma, a type of blood cancer.

The first recom­men­da­tion is for the use of VELCADE® (bor­tez­o­mib) as retreatment in adult patients who have pre­vi­ously responded to treat­ment with the same medicine.¹ The positive opinion re-enforces the ex­ist­ing data sup­porting the use of VELCADE® in this wider re­lapsed patient …

The American Society of Clinical Oncology will hold its 49^th annual meeting May 31 through June 4 in Chicago.

Similar to pre­vi­ous years, more than 25,000 clin­i­cal spe­cialists from all over the world are ex­pec­ted to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”

During the meeting, there will be pre­sen­ta­tions and seminars about all areas of cancer, in­clud­ing many focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists more than 60 myeloma-based pre­sen­ta­tions (included …